Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

Launched by TECHNISCHE UNIVERSITÄT DRESDEN · Jun 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two different chemotherapy treatments given before a stem cell transplant for people with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The goal is to find out which treatment works better and is easier to tolerate. Both treatments aim to prepare the body to accept healthy donor stem cells, and the study will look at important outcomes like how long patients live, how often the cancer stays away or comes back, how well the new stem cells grow, and whether patients develop graft-versus-host disease (a condition where the donor cells attack the patient’s body).

People who might be eligible for this study are adults aged 18 or older with AML or MDS who are scheduled to have a stem cell transplant soon. They should be at higher risk for side effects from strong chemotherapy, often because of their age (50 or older) or other health factors. Participants need to have a suitable stem cell donor available and be healthy enough to undergo the transplant, without serious heart problems or infections. Those who join will be randomly assigned to receive one of the two chemotherapy treatments before their transplant, followed by standard medicines to help prevent graft-versus-host disease. This trial is not yet recruiting, but it offers a chance to help improve treatment for people facing these serious blood cancers.

Gender

ALL

Eligibility criteria

• Main Inclusion Criteria:
• • 1. Informed consent signed by the patient capable of giving
• • 2. Patient scheduled for allogeneic transplantation within the next 3 weeks
• • 3. Age ≥ 18 years
• 4. AML or MDS according to WHO with indication for allogeneic HCT:
• • 1. AML in first or second complete remission (CR) or complete remission with incomplete hematologic recovery (CRi/CRh) or morphologic leukemia-free state (MLFS)
• • 2. MDS according to WHO
• 5. Increased risk for treatment-related toxicity by myeloablative conditioning according to at least one of the following criteria:
• • 1. Patients aged ≥ 50 years at transplant and/or
• • 2. HCT-CI \> 2 and/or
• • 3. AML or MDS scheduled for 2nd allogeneic HCT from different donor with minimum of 12 months after 1st allogeneic HCT
• 6. Availability of a suitable donor:
• • 1. Matched sibling donor (MSD) or
• • 2. matched unrelated donor (MUD, 10/10 HLA) or
• • 3. mismatched unrelated donor (MMUD, single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent -DQB1 mismatch (9/10) shown by confirmatory typing) or
• • 4. haploidentical family donor
• • 7. Planned GvHD prophylaxis with standard PTCy (with 50mg/kg body weight on days +3 and +4)
• • 8. No history of cardiac disease that preclude allogeneic HCT and absence of active symptoms, otherwise, documented left ventricular ejection fraction
• • 40 %.
• • 9. No need for supplementary oxygen on day of randomization
• Main Exclusion Criteria:
• • 1. Patients with acute promyelocytic leukemia with t(15;17)(q22;q12)
• • 2. Patients with graft failure after previous allogeneic HCT
• • 3. Patients with scheduled 2nd allogeneic HCT within 12 months after 1st allogeneic HCT
• • 4. Pretreatment with either melphalan or treosulfan within the last 12 months prior to randomization
• • 5. Planned TBI as part of conditioning
• 6. Severe organ dysfunction defined by either one of the following criteria:
• • 1. Serum bilirubin \> 1.5 × ULN (if not considered Gilbert-syndrome) or
• • 2. ALAT or ASAT \> 5 × ULN
• • 7. Uncontrolled infection at the time of randomization.
• • 8. Active viral hepatitis unless serology demonstrates clearance of infection. Occult or prior hepatitis B virus (HBV) infection, defined as negative hepatitis B surface antigen and positive total hepatitis core antibodies, may be included if HBV DNA is undetectable, provided that patients are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody after vaccination or prior cured hepatitis B are eligible. Patients for hepatitis C virus (HCV) antibody are eligible provided PCR if negative for HCV RNA.
• • 9. Pregnant or breastfeeding women